252 related articles for article (PubMed ID: 10383527)
1. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy.
Peters FT; Kuipers EJ; Ganesh S; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
Aliment Pharmacol Ther; 1999 Jul; 13(7):921-6. PubMed ID: 10383527
[TBL] [Abstract][Full Text] [Related]
2. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
Wani S; Sampliner RE; Weston AP; Mathur S; Hall M; Higbee A; Sharma P
Aliment Pharmacol Ther; 2005 Oct; 22(7):627-33. PubMed ID: 16181302
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study.
Peters FT; Ganesh S; Kuipers EJ; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
Gut; 1999 Oct; 45(4):489-94. PubMed ID: 10486353
[TBL] [Abstract][Full Text] [Related]
4. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease.
Schenk BE; Kuipers EJ; Klinkenberg-Knol EC; Eskes SA; Meuwissen SG
Am J Gastroenterol; 1999 Apr; 94(4):884-7. PubMed ID: 10201451
[TBL] [Abstract][Full Text] [Related]
5. Maximal acid reflux control for Barrett's oesophagus: feasible and effective.
Srinivasan R; Katz PO; Ramakrishnan A; Katzka DA; Vela MF; Castell DO
Aliment Pharmacol Ther; 2001 Apr; 15(4):519-24. PubMed ID: 11284781
[TBL] [Abstract][Full Text] [Related]
6. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
[TBL] [Abstract][Full Text] [Related]
7. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
8. Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients.
Qvigstad G; Arnestad JS; Brenna E; Waldum HL
Scand J Gastroenterol; 1998 Dec; 33(12):1244-8. PubMed ID: 9930386
[TBL] [Abstract][Full Text] [Related]
9. Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis.
Wu JC; Chan FK; Wong SK; Lee YT; Leung WK; Sung JJ
Aliment Pharmacol Ther; 2002 Mar; 16(3):545-52. PubMed ID: 11876709
[TBL] [Abstract][Full Text] [Related]
10. Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy.
Basu KK; Bale R; West KP; de Caestecker JS
Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1187-92. PubMed ID: 12439112
[TBL] [Abstract][Full Text] [Related]
11. Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus.
Peters FT; Ganesh S; Kuipers EJ; Sluiter WJ; Karrenbeld A; de Jager-Krikken A; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
Scand J Gastroenterol; 2000 Dec; 35(12):1238-44. PubMed ID: 11199360
[TBL] [Abstract][Full Text] [Related]
12. A 59-year-old woman with gastroesophageal reflux disease and Barrett esophagus.
Spechler SJ
JAMA; 2003 Jan 22-29; 289(4):466-75. PubMed ID: 12533126
[No Abstract] [Full Text] [Related]
13. Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan.
Muramatsu A; Azuma T; Okajima T; Ohtani M; Dojo M; Yamazaki Y; Kuriyama M
Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 1():102-6. PubMed ID: 15298614
[TBL] [Abstract][Full Text] [Related]
14. [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].
Sohn YH; Lee WS; Park CH; Joo YE; Kim HS; Choi SK; Rew JS; Kim SJ
Korean J Gastroenterol; 2006 Sep; 48(3):162-71. PubMed ID: 17047431
[TBL] [Abstract][Full Text] [Related]
15. Association between Helicobacter pylori and Barrett's esophagus, erosive esophagitis, and gastroesophageal reflux symptoms.
Rubenstein JH; Inadomi JM; Scheiman J; Schoenfeld P; Appelman H; Zhang M; Metko V; Kao JY
Clin Gastroenterol Hepatol; 2014 Feb; 12(2):239-45. PubMed ID: 23988686
[TBL] [Abstract][Full Text] [Related]
16. Patterns of 24-hour oesophageal acid exposure after acute withdrawal of acid suppression.
Orr WC; Mellow MH; Grossman MR
Aliment Pharmacol Ther; 1995 Oct; 9(5):571-4. PubMed ID: 8580280
[TBL] [Abstract][Full Text] [Related]
17. Is the sensitivity to gastric acid inhibition Helicobacter pylori status-dependent?
Smout AJ
Scand J Gastroenterol Suppl; 1998; 225():32-5. PubMed ID: 9515750
[TBL] [Abstract][Full Text] [Related]
18. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
Langtry HD; Wilde MI
Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317
[TBL] [Abstract][Full Text] [Related]
19. Different management for Helicobacter pylori positive and negative patients with gastro-oesophageal reflux disease?
Lee JM; O'Morain CA
Gut; 1998 Jul; 43 Suppl 1(Suppl 1):S14-20. PubMed ID: 9764033
[TBL] [Abstract][Full Text] [Related]
20. Acid suppression in the long-term treatment of peptic stricture and Barrett's oesophagus.
Lundell L
Digestion; 1992; 51 Suppl 1():49-58. PubMed ID: 1356869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
